Lymphovascular Invasion and Ductal In-situ Components in Operable Infiltrating Duct Carcinoma of Breast-
A Single Centre Experience
PC01-PC04
Correspondence
Ravindran Chirukandath,
Archana Kottekad Road Viyoor, Thrissur, Kerala, India.
E-mail: ravimen@gmail.com
Introduction: Lymphovascular Invasion (LVI) in carcinoma breast is a significant prognostic factor in invasive breast cancer, with respect to local and distant recurrence and poor survival. Infiltrating duct carcinoma with accompanying ductal carcinoma in-situ has shown significantly different expression patterns of Her2/neu, progesterone receptors and Ki67 than infiltrating duct carcinoma.
Aim: To associate the significance of LVI and concomitant in-situ component with the receptor status and clinicopathological characteristics of infiltrative duct carcinoma.
Materials and Methods: This retrospective study was conducted in a single unit in the Department Of General Surgery, Government Medical College, Thrissur, Kerala, India, for two months between June 2021 and July 2021 and data was analysed in August 2021. This study was conducted in a systematic manner to review all the operated infiltrative duct carcinoma patients from a single cohort in 100 patients based on surgical intervention. The collected data were entered in Microsoft Excel worksheet and the results were analysed statistically using Statistical Package of the Social Sciences (SPSS)-16. Chi-square test was used, considering p-value ≤0.05 as a significant.
Results: The mean age of the study population was 55.6±15 years with maximum number of patients above 60 years. In total 64% of the patients had tumour size of 2-5 cm (pT2) and 59% of the cases had no lymph nodal metastasis (pN0). 28 cases (28%) showed concomitant in-situ component and 37 cases showed lymphovascular invasion (37%). The presence of lymphovascular invasion, was found to be significantly associated with Her2 positivity (p=0.045). Concomitant in-situ component also seemed to increase the likelihood of lymphovascular invasion (p=0.0320). There was significant positive correlation observed between LVI and Her2 (r=0.238, p=0.045) and in-situ component (0.214; p=0.032). However, no significant association was observed between LVI and other clinicopathological variables.
Conclusion: The LVI is a significant prognostic factor in invasive breast cancer associated with poor survival and definitely carries a significant association with Her2 Status and also reflected on the concomitant in-situ carcinoma.